The estimated Net Worth of Samarth Kulkarni is at least $27.2 Milion dollars as of 15 April 2024. Samarth Kulkarni owns over 19,582 units of CRISPR Therapeutics AG stock worth over $10,346,870 and over the last 8 years he sold CRSP stock worth over $545,252. In addition, he makes $16,265,700 as Chief Executive Officer a Director at CRISPR Therapeutics AG.
Sign up
Samarth Kulkarni CRSP stock SEC Form 4 insiders trading
Samarth has made over 48 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 19,582 units of CRSP stock worth $374,408 on 15 April 2024.
The largest trade he's ever made was exercising 80,000 units of CRISPR Therapeutics AG stock on 3 December 2021 worth over $3,635,200. On average, Samarth trades about 12,869 units every 30 days since 2017. As of 15 April 2024 he still owns at least 227,704 units of CRISPR Therapeutics AG stock.
You can see the complete history of Samarth Kulkarni stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Samarth Kulkarni biography
Dr. Samarth Kulkarni Ph.D. serves as Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer since December 1, 2017. Previous to that, Dr. Kulkarni served as our President and Chief Business Officer from May 2017 to November 30, 2017 and, before that, as our Chief Business Officer from August 2015 when he joined our company. Prior to joining our company, Dr. Kulkarni was at McKinsey & Company from 2006 to July 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr. Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. Dr. Kulkarni has authored several publications in leading scientific and business journals. Kulkarni’s experience as our Chief Executive Officer, his previous experience as our President and Chief Business Officer, and his experience in the biopharmaceutical industry, qualifies him to serve on our Board of Directors.
What is the salary of Samarth Kulkarni?
As the Chief Executive Officer a Director of CRISPR Therapeutics AG, the total compensation of Samarth Kulkarni at CRISPR Therapeutics AG is $16,265,700. There are no executives at CRISPR Therapeutics AG getting paid more.
How old is Samarth Kulkarni?
Samarth Kulkarni is 41, he's been the Chief Executive Officer a Director of CRISPR Therapeutics AG since 2018. There are 13 older and 2 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
What's Samarth Kulkarni's mailing address?
Samarth's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON, MA, 02127.
Insiders trading at CRISPR Therapeutics AG
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani a Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
What does CRISPR Therapeutics AG's logo look like?
Complete history of Samarth Kulkarni stock trades at CRISPR Therapeutics AG, Black Diamond Therapeutics Inc a Repare Therapeutics
CRISPR Therapeutics AG executives and stock owners
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:
-
Samarth Kulkarni,
Chief Executive Officer, Director -
Lawrence Klein,
Chief Operating Officer, Chief Business Officer -
Tony Ho,
Executive Vice President - Research and Development -
James Kasinger,
General Counsel, Secretary -
Michael Tomsicek,
Chief Financial Officer -
Dr. Samarth Kulkarni,
CEO & Director -
Dr. Lawrence Otto Klein Ph.D.,
Chief Operating Officer -
James R. Kasinger,
Gen. Counsel & Sec. -
Rodger Novak,
Chairman of the Board, President, Co-Founder -
Dr. Rodger Novak M.D.,
Founder, Chairman & Pres -
Susan Kim,
IR Contact Officer -
Katherine High,
Independent Director -
John Greene,
Independent Director -
Simeon George,
Independent Director -
Bradley Bolzon,
Independent Director -
Ali Behbahani,
Independent Director -
Dr. Daniel G. Anderson Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Matthew Porteus M.D., Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Chad Cowan Ph.D.,
Scientific Founder -
Dr. Craig C. Mello Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Emmanuelle Marie Charpentier,
Co-Founder & Scientific Advisory Board Member -
Shaun Foy,
Founder -
Aktiengesellschaft Bayer Gl...,
-
Tyler Dylan Hyde,
Chief Legal Officer -
Pablo J Cagnoni,
Director -
Venture Capital Iv, L.P.Ver...,
-
Harbor Master Investors (Ca...,
10% owner -
Kurt Von Emster,
Director -
Sven Ante Lundberg,
Chief Scientific Officer -
Corp /De/ Celgene,
10% owner -
Kala Subramanian,
See Remarks -
Thomas Woiwode,
Director -
N Anthony Coles,
Director -
Plc Gsk,
10% owner -
Pharmaceuticals (Europe) Lt...,
-
Venture Capital Iv, L.P.Ver...,
-
Julianne Bruno,
Chief Operating Officer -
Brendan Smith,
Chief Financial Officer -
Venture Capital Iv, L.P.Ver...,
-
Venture Capital V, L.P.Vers...,
-
Naimish Patel,
Chief Medical Officer -
Harold Edward Fleming,
-
Maria Fardis,
-
Sandesh Mahatme,
-
Douglas A Treco,
-
Christian Rommel,
-
Phuong Khanh Morrow,
Chief Medical Officer -
Raju Prasad,
Chief Financial Officer